Preclinical research of the experimental preparation “Ferosel T”

Abstract

The results of preclinical studies of the new ferrodextran preparation “Ferosel T”, which contains ferrum and selenium, are presented. It has been established that at oral administration of ferrocellus T in a prophylactic dose of 2 ml/kg b.w. and the therapeutic dose of 4 ml/kg for 3 days in a row in the stomach of laboratory rats did not show toxic effects. No toxic effect of T ferrocellus is established at introducing it into the stomach in doses in 3 and 10 times higher than the therapeutic ones. Under conditions of subcutaneous administration of the drug, the death of white rats was not observed, only short-term inhibition of laboratory animals, which was prescribed the drug in a dose of 10 ml/kg b.w. It was established that in the preventive and optimal therapeutic doses the drug did not affect the detoxification function of the liver. In rats, which ferrocellus T was administered at maximum therapeutic and possibly toxic doses, the duration of hexenal sleep was for 32 and 35% higher relative to control values. The investigation of the emotional and behavioral reactions of laboratory animals after administration of ferrocellus T for 21 days in therapeutic and maximum therapeutic doses did not show a significant effect on the nervous system. In terms of hyperemia and swelling of the skin and the thickness of the skin, ferrocellus T in prophylactic and therapeutic doses upon application to rabbit skin did not cause local irritation. Separate injection of the drug “Ferosel T” by sub-planar way to guinea pigs in 0.1 ml. did not cause swollen reactions of the paws. As a result of the conducted research, no allergenic properties of the drug “Ferosel T” were found. In laboratory rats, which were introduced ferrosel T in the prophylactic dose of probable changes in the weight of the heart, liver, spleen and kidneys is not established. In rats, which were administered ferrocellus T in an optimal therapeutic dose, in comparison with control weights of the spleen and liver, respectively, was in 10.3 and 6.4% higher. When introducing ferrocellus T at the maximum therapeutic dose, the mass of the spleen and liver was in 14.0 and 15.0% higher, respectively. The results of the studies indicate that the drug “Ferosel T” is safe when used for the prevention and treatment of animals.